Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Grifols SA ( (GRFS) ) is now available.
On July 28, 2025, Grifols, S.A.’s Board of Directors approved an interim dividend payment of €0.15 per share for the 2025 profit. The payment will be distributed on August 13, 2025, with a total dividend amounting to €102,076,365.60. This decision reflects Grifols’ commitment to providing value to its shareholders and may impact investor sentiment positively.
The most recent analyst rating on (GRFS) stock is a Buy with a $15.45 price target. To see the full list of analyst forecasts on Grifols SA stock, see the GRFS Stock Forecast page.
Spark’s Take on GRFS Stock
According to Spark, TipRanks’ AI Analyst, GRFS is a Outperform.
Grifols SA’s strong technical momentum and positive earnings call results drive the overall score, despite valuation concerns and financial performance challenges such as high leverage and low net profit margins. The robust growth in key segments and strategic initiatives to improve cash flow and profitability are significant positives.
To see Spark’s full report on GRFS stock, click here.
More about Grifols SA
Grifols, S.A. is a prominent company in the healthcare sector, specializing in the production of plasma-derived medicines and other biological products. The company focuses on enhancing the health and well-being of people worldwide, with a strong market presence in the biopharmaceutical industry.
Average Trading Volume: 861,321
Technical Sentiment Signal: Buy
Current Market Cap: $8.69B
For detailed information about GRFS stock, go to TipRanks’ Stock Analysis page.